Breast cancer and mutation in the ataxia telangiectasia mutated gene: a case report
DOI:
https://doi.org/10.24265/horizmed.2023.v23n1.11Keywords:
breast neoplasms, mutation, genes, ataxia telangiectasiaAbstract
Among women, breast cancer is the most common cancer in the world, accounting for 25.7 % of all cancers and thus making it a topic of interest in public health. Breast cancer is a complex, heterogeneous genetic disease and, in the vast majority of cases, of unknown etiology. Around 7 % of breast cancer cases in the general population present a susceptibility gene mutation of Mendelian inheritance. The ataxia telangiectasia mutated (ATM) gene mutation is found in
less than 1 % of the general population, and association studies conducted with controls have shown that these alleles are characterized by a moderate risk (RR: 2 ‐ 4) for hereditary cancer. Mutations in ATM incompletely cosegregate the disease, with an estimated 15 % of mutation carriers in this gene developing cancer. The incomplete penetrance of ATM, as well
as other moderate‐risk genes, supports that they follow a polygenic model of cancer susceptibility. We report the case of a 35‐year‐old woman diagnosed with metachronous bilateral breast carcinoma—T4b N1 M0 stage IIIB left breast and T1c N0 stage I right breast, intrinsic luminal B subtype, HER2 overexpression and pathogenic variant of ATM gene c.7913 G>A, p. Trp2638*—who was treated with neoadjuvant chemotherapy, followed by mastectomy, sentinel node biopsy and radiotherapy. The objective of this case report is to describe the clinicopathological characteristics of breast cancer and its association with moderate‐risk gene mutations.
Downloads
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
World Health Organization. Breast cancer [Internet]. Geneva: WHO. 2021 [citado 30 de enero de 2023]. Disponible en: https://www.who.int/news-room/fact-sheets/detail/breast-cancer.
Madigan MP, Ziegler RG, Benichou J, Byrne C, Hoover RN. Proportion of Breast Cancer Cases in the United States Explained by Well-Established Risk Factors. J Natl Cancer Inst. 1995;87(22):1681-5.
Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat Genet. 2008;40(1):17-22.
Hollestelle A, Wasielewski M, Martens JW, Schutte M. Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev. 2010;20(3):268-76.
Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, Risk Prediction, and Targeted Prevention of Breast Cancer. N Engl J Med. 2008;358(26):2796-803.
Ghoussaini M, Fletcher O, Michailidou K, Turnbull C, Schmidt MK, Dicks E, et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44(3):312-8.
ClinVar. VCV000141233.32 [Internet]. National Library of Medicine. 2023 [citado 30 de enero de 2023]. Disponible en: https://www.ncbi.nlm.nih.gov/clinvar/variation/141233/?oq=ATM[gene]+AND+c.7913G%3EA[varname]+&m=NM_000051.4(ATM):c.7913G%3EA%20(p.Trp2638Ter)#id_third.
Gatti R, Perlman S. Ataxia-Telangiectasia. En: Adam MP, Everman DB, Mirzaa GM, Pagon RA, Wallace SE, Bean LJ, et al., editores. GeneReviews. Seattle (WA): University of Washington, Seattle; 1993.
Easton DF, Pharoah PDP, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, et al. Gene-Panel Sequencing and the Prediction of Breast-Cancer Risk. N Engl J Med. 2015;372(23):2243-57.
Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol. 2016;34(13):1460-68.
Broeks A, Urbanus JH, Floore AN, Dahler EC, Klijn JG, Rutgers EJ, et al. ATM-Heterozygous Germline Mutations Contribute to Breast Cancer-Susceptibility. Am J Hum Genet. 2000;66(2):494-500.
Kapoor NS, Curcio LD, Blakemore CA, Bremner AK, McFarland RE, West JG, et al. Multigene Panel Testing Detects Equal Rates of Pathogenic BRCA1/2 Mutations and has a Higher Diagnostic Yield Compared to Limited BRCA1/2 Analysis Alone in Patients at Risk for Hereditary Breast Cancer. Ann Surg Oncol. 2015;22(10):3282-88.
Fletcher O, Johnson N, dos Santos Silva I, Orr N, Ashworth A, Nevanlinna H, et al. Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. Cancer Epidemiol Biomark Prev 2010;19(9):2143-51.
Goldgar DE, Healey S, Dowty JG, Da Silva L, Chen X, Spurdle AB, et al. Rare variants in the ATMgene and risk of breast cancer. Breast Cancer Res. 2011;13(4):R73.
Ahmed M, Rahman N. ATM and breast cancer susceptibility. Oncogene. 2006;25(43):5906-11.
Gutiérrez-Enríquez S, Fernet M, Dork T, Bremer M, Lauge A, Stoppa- Lyonnet D, et al. Functional consequences of ATM sequence variants for chromosomal radiosensitivity. Genes Chromosomes Cancer. 2004;40(2):109-19.
Bernstein JL, Haile RW, Stovall M, Boice JD Jr, Shore RE, Langholz B, et al. Radiation Exposure, the ATM Gene, and Contralateral Breast Cancer in the Women Environmental Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2010;102(7):475-83.
Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJS, et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 2010;116(22):4578-87.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Horizonte Médico (Lima)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Horizonte Médico (Lima) (Horiz. Med.) journal’s research outputs are published free of charge and are freely available to download under the open access model, aimed at disseminating works and experiences developed in biomedical and public health areas, both nationally and internationally, and promoting research in the different fields of human medicine. All manuscripts accepted and published in the journal are distributed free of charge under the terms of a Creative Commons license – Attribution 4.0 International (CC BY 4.0).
